Crossmark

Single-nucleotide variants as potential prognostic biomarkers in newly diagnosed multiple myeloma patients

Crossref DOI link: https://doi.org/10.1016/j.htct.2026.106464

Published Print: 2026-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Garrido, David https://orcid.org/0000-0002-7384-1236
Ledesma, Martín https://orcid.org/0000-0002-9080-2108
Stella, Flavia https://orcid.org/0000-0002-5132-6997
Galvano, Camila https://orcid.org/0000-0001-7702-3129
Lopresti, Sergio https://orcid.org/0000-0003-1394-5292
Riva, Eloísa https://orcid.org/0000-0002-4750-034X
Fundia, Ariela https://orcid.org/0009-0009-4000-0519
Slavutsky, Irma https://orcid.org/0000-0002-0611-2367
Funding

Funding for this research was provided by:

Paula and Rodger Riney Foundation

International Myeloma Society

National Scientific and Technical Research Council
License Information

Text and Data Mining valid from 2026-07-01

Text and Data Mining valid from 2026-07-01

Version of Record valid from 2026-04-10
More Information

This article is maintained by: Elsevier

Article Title: Single-nucleotide variants as potential prognostic biomarkers in newly diagnosed multiple myeloma patients

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2026.106464

Content Type: article

Copyright: © 2026 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U.